Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
2,240 total articles
Goodyear (GT) is cheap on several enterprise multiples after a string of operational headwinds. Recent asset sales and the 'Goodyear Forward' program create a credible line of sight to improved margins and cash generation. This trade idea lays out a mid-term long with precise entry, stop and target calibrated to current technicals and the company's…
Bath & Body Works is trading at bargain multiples relative to its cash-generation ability. With free cash flow of $946M, an EV/EBITDA of 5.7 and a P/E near 6.7, the market has overly penalized BBWI for a failed adjacency strategy and short-term earnings misses. This trade idea upgrades the stock to a buy for a mid-term rebound, with a precise entry…
Mitek Systems operates one of the clearest durable niches in fintech: mobile capture and identity verification. With roughly 50% penetration at U.S. banks, positive cash flow and a sub-$700M market cap, MITK is priced for steady growth. This trade idea lays out an entry at $15, a $19 target aligned with recent analyst work, and a $13 stop, with a l…
Relay Therapeutics' zovegalisib just cleared a major regulatory hurdle with FDA Breakthrough Therapy designation, validating clinical benefit signals and compressing timelines. With a market cap around $1.82B, bullish technicals and heavy short interest, this is a high-reward, high-risk mid-term trade aiming to capture a re-rating on upcoming data …
CoreWeave reported blistering revenue growth but stunned markets with a $30-35B capex plan for 2026 and stretched balance-sheet metrics. With operating losses, negative free cash flow of $7.25B, and debt levels implied by a 6.48 debt-to-equity ratio, this is a high-conviction, mid-term short trade set for 45 trading days. Trade size should be limit…
Woodside is transitioning from build-out to cash generation. Recent offtakes for its Louisiana LNG project and incremental long-term deals (Uniper, BOTAŞ) plus a 4.65% yield make a disciplined long entry attractive over the next 45 trading days. Technicals are hot — so size accordingly and use a clear stop.
Abercrombie & Fitch (ANF) is trading near $96 with strong cash flow, a lean balance sheet and an EV/EBITDA around 4.3. Fundamentals show high ROE (≈39.6%) and free cash flow of $384.5M, implying the stock is priced for modest growth. This trade idea argues for a long position sized prudently, with an entry at $96.00, stop at $85.00 and target at $1…
Berkshire Hathaway looks reasonably priced at roughly $487.50 with a P/E near 15.7, a modest P/B of ~1.5 and a near‑record cash war chest of $373.3B. Given the new leadership under Greg Abel and the company’s diversified earnings streams, a measured long position offers attractive asymmetry. Trade plan: enter at $487.50, target $540.00, stop $455.1…
Carnival (CCL) offers a pragmatic income trade: a modest current yield, below-market valuation (P/E ~14), and meaningful free cash flow ($2.6B) support a dividend-focused long trade. Technicals are soft but manageable; use a conservative stop and target near the 52-week high for a low-risk, income-oriented position over the next 180 trading days.
UroGen (URGN) recently re-rated as ZUSDURI builds clinical credibility for treating recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC). With a market cap near $980M, durable efficacy data and an experienced commercialization push, ZUSDURI has the potential to replace TURBT in specific patient cohorts, supporting upsid…
USANA Health Sciences (USNA) trades at a valuation that looks disconnected from its balance-sheet strength and recent top-line momentum. With no debt, positive free cash flow ($18.7M last reported), an EV/EBITDA of ~3.0 and a market cap around $355M, USNA offers a low-leverage way to play recovery in the functional supplements market. This trade id…
Antero Midstream (AM) is trading near its 52-week highs on durable free cash flow, an accretive $1.1B HG Mid acquisition and management guidance for higher adjusted EBITDA and FCF in 2026. The combination of predictable midstream cash generation, balance-sheet improvement and active capital returns makes a tactical long attractive over a 180-tradin…
Cushman & Wakefield (CWK) is a leveraged but cash-generative commercial real estate services firm where valuation and free cash flow offer an asymmetric trade setup today. The recent lawsuit headline has injected volatility, but fundamentals - $293M in free cash flow, EV/EBITDA ~9, and EV/FCF in the mid-teens - argue for a long-biased, risk-defined…
IAMGOLD (IAG) reported record production in 2025, is guiding for further strong output in 2026, and sits on a relatively clean balance sheet. With gold above $4,700/oz and operational momentum, the stock looks attractive for a mid-term swing trade. Entry, target and stop are laid out below, along with catalysts, valuation framing and balanced risks…
Leidos (LDOS) is a market-cap ~ $22.3B defense and government-services platform trading at ~15.8x earnings with $1.63B free cash flow and a recently announced $2.4B acquisition that expands exposure to critical power infrastructure. We view the current pullback as a long-term (180 trading days) buying opportunity, but the trade rests on deal execut…
Walmart is a defensive giant with pricing power and operational scale, but a bumpy tariff backdrop and elevated valuation justify a measured, swing-oriented long. This trade targets a disciplined pullback entry, a reasonable upside to recent highs, and a stop that respects near-term volatility.
Equinor is trading near a 52-week high on positive headlines — buybacks and fresh Norwegian licenses — but momentum has room to run. Market-cap ~$81.98B, P/E ~16, and a 3.49% yield support a mid-term long. Trade plan provided for a mid-term (45 trading days) swing with defined risk controls.
Barclays (BCS) looks attractively priced after the market cooled off. The shares trade at about $23.36 with a market cap near $80.6B, a P/B around 0.91 and P/E roughly 10. With technical indicators showing oversold momentum and a wide 52-week range, this trade targets a re-rating toward the prior highs while keeping a tight stop to manage macro and…
Amylyx (AMLX) presents a high-risk, high-reward trade: the stock is trading at $15.05 with roughly $8.73 in cash per share and a $1.65B market cap. Positive LUCIDITY data expected by Q3 could materially re-rate shares; downside is meaningful if the readout disappoints or commercialization progress for other programs stalls. Our trade plan targets $…
Western Digital sits at the intersection of hyperscale storage demand and legacy HDD scale economics. With multi-year cloud contracts, improving margins and a market cap near $88.5B, WDC is a plausible play on continued AI data-center spending. This trade idea lays out an actionable long with a clear entry, stop and target, plus the catalysts and r…
StoneCo's shares trade at $14.29 with a sub-9x P/E and a $3.88B market cap after a volatile week. I am adding to my position because a modest repurchase program would translate into a double-digit buyback yield at today's valuation — and the company’s recent operating beats support that play.
Western Digital (WDC) looks like a compelling buy on the pullback caused by Sandisk-related share sales. Strong free cash flow, fat returns on equity, and multi-year data-center demand for high-capacity storage give WDC a credible path higher. I’m upgrading the trade rating to long with an entry at $263.50, stop at $210.00 and a target of $380.00 o…
Moderna cleared a major legal overhang with a $950M settlement and has an FDA PDUFA goal date of 08/05/2026 on its seasonal flu application. With a market cap near $23.4B, negative free cash flow narrowing, and strong technical momentum, we initiate a buy with a mid-term horizon and defined risk controls.
DexCom looks set to benefit from an underappreciated demand tailwind as CGMs (continuous glucose monitors) are being prescribed alongside GLP-1 therapies. The stock is trading around $73, offers solid free cash flow and high ROE, and technicals show constructive momentum. This trade lays out a precise entry, stop and target for a long position over…
Simmons First (SFNC) is showing the hallmarks of a genuine turnaround: strong free cash flow, a rising dividend and a valuation below tangible book. The bank remains unprofitable on the headline EPS line, but low leverage, an attractive yield and a compact market cap create an asymmetric risk-reward for long-term value hunters. This is an upgrade t…
